Current Opinion in Gastroenterology最新文献_第4页

Startups and the next frontier of inflammatory bowel disease therapy: a guide for the brave. 初创公司和炎症性肠病治疗的下一个前沿：勇敢的指南。

IF 2.6 3区医学

Current Opinion in Gastroenterology Pub Date : 2025-07-01 Epub Date: 2025-05-02 DOI: 10.1097/MOG.0000000000001100

Vladimir Lamm

{"title":"Startups and the next frontier of inflammatory bowel disease therapy: a guide for the brave.","authors":"Vladimir Lamm","doi":"10.1097/MOG.0000000000001100","DOIUrl":"10.1097/MOG.0000000000001100","url":null,"abstract":"Purpose of review: This review explores the evolving landscape of inflammatory bowel disease (IBD) therapy, particularly through the lens of startups that are pushing the boundaries of current treatment paradigms. By discussing the challenges and opportunities faced by startups, this review seeks to provide insights for aspiring entrepreneurs and innovators in the IBD space.Recent findings: The landscape of IBD is rapidly evolving, with innovative solutions ranging from novel therapeutics to digital health platforms. An analysis of recent SBIR award winners highlights emerging trends, including microbiome-based therapies, targeted small molecules, and advanced drug delivery systems like hydrogels. Digital health solutions, such as smart monitoring tools and AI-assisted treatment selection are gaining traction. IBD startups are playing a crucial role in cost reduction through competition, streamlining drug development, and treatment personalization. Despite regulatory, financial, and funding challenges, startups are driving the next phase of IBD innovation.Summary: The future of IBD therapy is being driven by innovative start-ups that are challenging the status quo in IBD treatment. These companies are addressing critical gaps in therapy by focusing on novel drug targets, improved drug delivery, and precision medicine. While startups face many challenges including high research and development (R&D) costs, regulatory hurdles, and funding, they continue to be at the forefront of IBD innovation. Their success could potentially lead to more affordable and effective therapies. By drawing on examples like the nutraceutical company, Evinature, my own personal experience as technical lead of Edulis, a startup focused on localized IBD therapy, and perspective from the head of the Crohn's and Colitis Foundation's IBD Ventures, this review aims to provide insights for those looking to innovate in IBD.","PeriodicalId":50607,"journal":{"name":"Current Opinion in Gastroenterology","volume":" ","pages":"190-200"},"PeriodicalIF":2.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144128092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gut-directed therapeutics in inflammatory bowel disease. 炎症性肠病的肠道定向治疗。

IF 2.6 3区医学

Current Opinion in Gastroenterology Pub Date : 2025-07-01 Epub Date: 2025-04-25 DOI: 10.1097/MOG.0000000000001099

Christina Kratschmer, David T Curiel, Matthew A Ciorba

{"title":"Gut-directed therapeutics in inflammatory bowel disease.","authors":"Christina Kratschmer, David T Curiel, Matthew A Ciorba","doi":"10.1097/MOG.0000000000001099","DOIUrl":"10.1097/MOG.0000000000001099","url":null,"abstract":"Purpose of review: Tissue-directed therapies (TDTs) provide potential advantages, including improved tolerance, safety, and efficacy. This review provides a conceptual framework for understanding intestinal TDT and summarizes the current landscape of TDT in inflammatory bowel disease (IBD).Recent findings: Vedolizumab, a mAb targeting the gut homing α4β7 integrin, served as revolutionary proof-of-principle for the power of advanced TDT in IBD. The development of other monoclonal antibodies targeting cell adhesion molecules followed including abrilumab (α4β7), etrolizumab (β7), and ontamalimab (MAdCAM-1). MORF-057, an oral small molecule inhibitor of α4β7, is now in development for ulcerative colitis. Efforts have also been made toward gut specific JAK inhibitors. Microbiome-based therapies, including engineered probiotics, bacteriophages, and postbiotics, are gaining interest. There are also a number of innovative drug delivery methods, including engineered yeast, hydrogels, and nanoparticles, and viral-based gene therapy.Summary: Gut-targeted therapies range from novel variations on traditional drugs (i.e., mAbs and small molecules) to microbiome-based therapeutics and engineered delivery systems. They can be used alone or in combination with currently available therapies. Future directions should focus on the development of tried-and-true modalities (mAbs, small molecules) as well as the microbiome and more innovative delivery systems.","PeriodicalId":50607,"journal":{"name":"Current Opinion in Gastroenterology","volume":" ","pages":"201-207"},"PeriodicalIF":2.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12164124/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144056806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of reflux hypersensitivity. 反流超敏反应的处理。

IF 2.6 3区医学

Current Opinion in Gastroenterology Pub Date : 2025-07-01 Epub Date: 2025-05-21 DOI: 10.1097/MOG.0000000000001107

Sudharshan Achalu, Adily N Elmi, Afrin N Kamal

{"title":"Management of reflux hypersensitivity.","authors":"Sudharshan Achalu, Adily N Elmi, Afrin N Kamal","doi":"10.1097/MOG.0000000000001107","DOIUrl":"10.1097/MOG.0000000000001107","url":null,"abstract":"Purpose of review: The challenges in distinguishing reflux hypersensitivity (RH) from other functional esophageal disorders demand a comprehensive understanding of RH. This review aims to discuss the latest practices in diagnosis and management of RH, examining the pathophysiology, diagnostic criteria, and evolving treatment strategies for RH, with an emphasis on the role of effective patient-physician communication.Recent findings: Esophageal hypersensitivity appears to play a significant role in symptoms generation for RH patients. Diagnostic algorithms have improved with updates from the Lyon consensus. Management strategies including treatments with neuromodulators, proton-pump inhibitors, behavioral interventions, and antireflux surgery are potential therapeutic options for patients with RH.Summary: Effective RH management requires a patient-centered approach that considers possible pharmacologic, behavioral, and surgical strategies. Effective patient-physician communication is essential to educate patients and address their concerns about neuromodulators, and to reframe treatment strategies to target esophageal hypersensitivity rather than a psychiatric disorder.","PeriodicalId":50607,"journal":{"name":"Current Opinion in Gastroenterology","volume":" ","pages":"229-233"},"PeriodicalIF":2.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144129459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chromatin profiling to identify biomarkers in inflammatory bowel diseases. 鉴定炎症性肠病生物标志物的染色质谱分析。

IF 2.6 3区医学

Current Opinion in Gastroenterology Pub Date : 2025-07-01 Epub Date: 2025-05-02 DOI: 10.1097/MOG.0000000000001104

Ayesh Awad, Aaron J Alcala, Martis W Cowles, Shehzad Z Sheikh

{"title":"Chromatin profiling to identify biomarkers in inflammatory bowel diseases.","authors":"Ayesh Awad, Aaron J Alcala, Martis W Cowles, Shehzad Z Sheikh","doi":"10.1097/MOG.0000000000001104","DOIUrl":"10.1097/MOG.0000000000001104","url":null,"abstract":"Purpose of review: Chromatin plays a critical role in gene regulation and disease pathogenesis. In inflammatory bowel disease (IBD), alterations in chromatin structure contribute to disease heterogeneity and impact treatment responses. This review explores chromatin accessibility and chromatin-associated proteins as biomarkers for IBD and highlights recent technological advancements enabling targeted biomarker discovery and novel therapies.Recent findings: Advancements in high-throughput sequencing have enabled genome-wide profiling of chromatin interactions in IBD. Studies have identified distinct chromatin landscapes in Crohn's disease (CD) and ulcerative colitis (UC), revealing stable regulatory shifts independent of inflammation.Summary: Chromatin profiling offers a novel approach for identifying biomarkers and therapeutic targets in IBD. Integrating chromatin accessibility data with transcriptomic and epigenomic analyses can refine disease classification and guide personalized treatment strategies. Emerging techniques compatible with formalin-fixed paraffin-embedded (FFPE) samples enhance clinical applicability, bridging the gap between molecular research and precision gastroenterology.","PeriodicalId":50607,"journal":{"name":"Current Opinion in Gastroenterology","volume":" ","pages":"216-222"},"PeriodicalIF":2.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12140863/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143996837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emerging role of peroxisome proliferator-activated receptor agonists in the treatment of cholestatic liver disease. 过氧化物酶体增殖物激活受体激动剂在治疗胆汁淤积性肝病中的新作用。

IF 2.6 3区医学

Current Opinion in Gastroenterology Pub Date : 2025-07-01 Epub Date: 2025-06-05 DOI: 10.1097/MOG.0000000000001109

Sheena Bhushan, Kris V Kowdley

{"title":"Emerging role of peroxisome proliferator-activated receptor agonists in the treatment of cholestatic liver disease.","authors":"Sheena Bhushan, Kris V Kowdley","doi":"10.1097/MOG.0000000000001109","DOIUrl":"10.1097/MOG.0000000000001109","url":null,"abstract":"Purpose of review: Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are rare, chronic cholestatic diseases associated with significant morbidity. While previously approved therapies for PBC, including ursodeoxycholic acid (UDCA) and obeticholic acid (OCA) have substantially altered the natural course of the disease and improved patient survival, they have several limitations including an incomplete therapeutic response, patient intolerance and a lack of symptom relief.Recent findings: Peroxisome proliferator-activated receptor (PPAR) agonists have emerged as promising therapeutic agents capable of achieving biochemical remission and alleviating debilitating symptoms such as pruritus. Elafibranor and Seladelpar were recently granted accelerated approval by the FDA as second-line treatment option for PBC. Although no treatment has yet received approval for PSC, several PPAR agonists have been evaluated in clinical trials.Summary: This review highlights the evolving role of PPAR agonists as second-line agents for PBC and investigational treatments for PSC.","PeriodicalId":50607,"journal":{"name":"Current Opinion in Gastroenterology","volume":"41 4","pages":"281-288"},"PeriodicalIF":2.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144227466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Surgical versus endoscopic management of esophageal perforation. 食管穿孔的手术与内镜治疗。

IF 2.6 3区医学

Current Opinion in Gastroenterology Pub Date : 2025-07-01 Epub Date: 2025-04-23 DOI: 10.1097/MOG.0000000000001095

Kevin J Wang, Evelyn V Alexander, Stephanie G Worrell

{"title":"Surgical versus endoscopic management of esophageal perforation.","authors":"Kevin J Wang, Evelyn V Alexander, Stephanie G Worrell","doi":"10.1097/MOG.0000000000001095","DOIUrl":"10.1097/MOG.0000000000001095","url":null,"abstract":"Purpose of review: The management of esophageal perforation is a topic of debate, as there now are viable surgical and endoscopic options. Historically, surgical management had been considered the standard of care for these perforations, but such surgical management can be associated with considerable morbidity. In this report, we explore contemporary options for the care of patients with esophageal perforations.Recent findings: Innovations in endoscopic therapies, including self-expanding metal and plastic stents, over-the-scope clips, vacuum therapy, and endoscopic suturing have expanded treatment options for esophageal perforations. These approaches are particularly beneficial for selected patients with early, contained perforations, offering reduced morbidity and shorter hospital stays. However, surgical intervention remains essential in cases of extensive contamination, necrosis, or delayed diagnosis. A growing body of evidence supports a patient-specific approach, integrating both traditional and emerging interventions.Summary: The management of esophageal perforation is evolving with the increasing use of minimally invasive endoscopic techniques. However, surgical repair remains the definitive treatment in patients with hemodynamic instability or extensive contamination. Timely intervention is critical, as delayed diagnosis significantly increases morbidity and mortality. A tailored approach, incorporating patient-specific factors and nature of the disease, ensures optimal outcomes.","PeriodicalId":50607,"journal":{"name":"Current Opinion in Gastroenterology","volume":" ","pages":"239-244"},"PeriodicalIF":2.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144056266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hematopoietic stem cell transplantation in Crohn's disease: a comprehensive review. 造血干细胞移植治疗克罗恩病的综述

IF 2.6 3区医学

Current Opinion in Gastroenterology Pub Date : 2025-07-01 Epub Date: 2025-04-14 DOI: 10.1097/MOG.0000000000001096

Akshita Gupta, Elena Ricart, Louis Cohen

{"title":"Hematopoietic stem cell transplantation in Crohn's disease: a comprehensive review.","authors":"Akshita Gupta, Elena Ricart, Louis Cohen","doi":"10.1097/MOG.0000000000001096","DOIUrl":"10.1097/MOG.0000000000001096","url":null,"abstract":"Purpose of review: Despite advances in medical therapies for the treatment of Crohn's disease (CD), 20-30% of patients fail to respond to these therapies (i.e. refractory CD). Medically refractory CD leads to significant disability increasing morbidity and mortality. To prevent the disability of refractory CD, hematopoietic stem cell transplantation (SCT) has emerged as a therapeutic strategy.Recent findings: Autologous (auto-SCT) and allogeneic SCT (allo-SCT) have been explored in clinical trials for refractory CD patients. We will review the stem cell transplant process, how each part of stem cell transplantation affects clinical efficacy and safety, and how specific clinical trials advanced our understanding of the role of stem cell transplant in the treatment of refractory CD.Summary: As multiple clinical trials using the same auto-SCT protocol demonstrated auto-SCT as clinically efficacious for refractory CD it supports that this treatment may be adopted as standard of care for select patients with refractory CD. To establish auto-SCT as a standard therapy will require the creation of international registries to track long-term SCT outcomes and translational studies to refine SCT protocols for CD patients as a cellular therapy that truly restores healthy intestinal immune cell populations from hematopoietic stem cells.","PeriodicalId":50607,"journal":{"name":"Current Opinion in Gastroenterology","volume":" ","pages":"175-181"},"PeriodicalIF":2.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12147729/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144057237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Aminotransferase levels in clinical practice - what is normal? 临床实践中的转氨酶水平-什么是正常的？

IF 2.6 3区医学

Current Opinion in Gastroenterology Pub Date : 2025-07-01 Epub Date: 2025-04-09 DOI: 10.1097/MOG.0000000000001094

Jad Allam, Don C Rockey

{"title":"Aminotransferase levels in clinical practice - what is normal?","authors":"Jad Allam, Don C Rockey","doi":"10.1097/MOG.0000000000001094","DOIUrl":"10.1097/MOG.0000000000001094","url":null,"abstract":"Purpose of review: No universal consensus exists as to what the upper limit of normal for alanine aminotransferase (ALT) should be. The purpose of this review is to provide insight on the wide variation in the upper limit of normal for ALT, and to highlight key elements resulting in these differences. We also wish to point to potential solutions for standardizing the upper limit of normal.Recent findings: There are considerable differences in the values for what constitutes a 'normal' ALT serum concentration set by laboratories, and reference values may vary two-fold between different institutions (from 30 to 60 U/l). Key reasons for this include using markedly different reference populations to establish the bounds of normal, and differences in analyzers and assays used to quantify ALT levels. A number of studies have attempted to re-evaluate the upper limit of normal and propose new cut-offs that would allow better detection of liver disease.Summary: The upper limit of normal for ALT continues to vary from one laboratory to another. Despite ongoing efforts, there is still an unmet demand to standardize ALT reference ranges, which is critical for clinical practice. More rigorous inclusion criteria for reference population studies and harmonization in analyzer differences is required to standardize ALT reference ranges universally.","PeriodicalId":50607,"journal":{"name":"Current Opinion in Gastroenterology","volume":" ","pages":"260-264"},"PeriodicalIF":2.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144006522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The current state of esophageal lichen planus. 食管扁平苔藓的现状。

IF 2.6 3区医学

Current Opinion in Gastroenterology Pub Date : 2025-07-01 Epub Date: 2025-05-14 DOI: 10.1097/MOG.0000000000001112

Megan B Ghai, Nasim Parsa, Joshua A Sloan

{"title":"The current state of esophageal lichen planus.","authors":"Megan B Ghai, Nasim Parsa, Joshua A Sloan","doi":"10.1097/MOG.0000000000001112","DOIUrl":"10.1097/MOG.0000000000001112","url":null,"abstract":"Purpose of review: The purpose of this review article is to: describe the clinical manifestations of esophageal lichen planus (ELP), understand its epidemiological risk factors, elaborate the common endoscopic and histopathologic findings of ELP, summarize current thinking on treatment and surveillance, and understand the long-term sequelae of ELP.Recent findings: A combination of clinical, endoscopic, and histopathologic findings are required to make a diagnosis of ELP. While there is no consensus on management of ELP, there is evidence of clinical and endoscopic improvement with the use of topical steroids among other therapies. There is a known risk of malignant transformation of ELP to esophageal squamous cell carcinoma (ESCC).Summary: ELP is an idiopathic condition that primarily affects Caucasian females ages 50-70 years. This review of current literature suggests that a combination of clinical, endoscopic, and histologic findings are required to make a diagnosis; topical steroids with or without esophageal dilation show overall improvement of ELP; and endoscopic surveillance to monitor for ESCC is recommended.","PeriodicalId":50607,"journal":{"name":"Current Opinion in Gastroenterology","volume":" ","pages":"223-228"},"PeriodicalIF":2.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144128093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Update on laryngopharyngeal reflux disease. 喉咽反流病最新进展。

IF 2.6 3区医学

Current Opinion in Gastroenterology Pub Date : 2025-07-01 Epub Date: 2025-05-14 DOI: 10.1097/MOG.0000000000001108

Miguel A Algara, Walter W Chan

{"title":"Update on laryngopharyngeal reflux disease.","authors":"Miguel A Algara, Walter W Chan","doi":"10.1097/MOG.0000000000001108","DOIUrl":"10.1097/MOG.0000000000001108","url":null,"abstract":"Purpose of review: Chronic laryngopharyngeal symptoms (LPS) are increasingly prevalent presentations to gastroenterologists' offices, and clinicians often make a presumptive diagnosis of laryngopharyngeal reflux disease (LPRD) based on LPS symptoms or laryngoscopic findings alone. Such presumptive diagnoses of LPRD often are incorrect, and establishing the correct diagnosis poses significant challenges for clinicians. This review addresses the timely need for advances in evaluating and managing LPS/LPRD, given their diagnostic complexity and the healthcare burden of ineffective empiric treatments.Recent findings: Recent evidence emphasizes the diverse etiologies of LPS including LPRD, oropharyngeal or other airway pathologies, allergic conditions, and cognitive-affective processes or altered brain-larynx interaction. The diagnostic approach should be individualized and multimodal, including upfront reflux testing over empiric acid suppression trials for possible LPRD, given the poor correlation between LPS and objective evidence of reflux. Predictive models and risk stratification tools such as the COuGH RefluX score show promise to help guide testing and therapeutic strategies. Reflux testing modalities include wireless pH monitoring and impedance-based testing (traditional impedance-pH or combined hypopharyngeal-esophageal reflux monitoring). Biochemical testing for salivary pepsin may also offer adjunctive value. Management should include antireflux strategies for those with objectively-proven LPRD, alongside treatments targeting nonreflux mechanisms of LPS, such as voice therapy, neuromodulation, and behavioral therapy.Summary: An individualized, multidisciplinary approach is essential in managing LPS/LPRD. Objective reflux testing improves diagnostic accuracy, avoids unnecessary therapies, and enables tailored treatment. Future research should further refine diagnostic thresholds, validate risk stratification tools, and explore novel therapeutic targets to optimize outcomes.","PeriodicalId":50607,"journal":{"name":"Current Opinion in Gastroenterology","volume":" ","pages":"251-259"},"PeriodicalIF":2.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144128409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0